HUP9900018A1 - Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására - Google Patents

Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására

Info

Publication number
HUP9900018A1
HUP9900018A1 HU9900018A HUP9900018A HUP9900018A1 HU P9900018 A1 HUP9900018 A1 HU P9900018A1 HU 9900018 A HU9900018 A HU 9900018A HU P9900018 A HUP9900018 A HU P9900018A HU P9900018 A1 HUP9900018 A1 HU P9900018A1
Authority
HU
Hungary
Prior art keywords
replication
dna molecule
circular dna
gene therapy
preparing same
Prior art date
Application number
HU9900018A
Other languages
English (en)
Inventor
Joël Crouzet
Fabienne Soubrier
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9482580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9900018(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Publication of HUP9900018A1 publication Critical patent/HUP9900018A1/hu
Publication of HUP9900018A3 publication Critical patent/HUP9900018A3/hu
Publication of HU224400B1 publication Critical patent/HU224400B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

A találmány tárgya egy cirkűláris alakú DNS-mőlekűla, amely agénterápiában hasznős, és amely legalább egy kívántnűkleinsavszekvenciát tartalmaz, azzal jellemezve, hőgy areplikációját lehetővé tevő terület egy őlyan replikációs őrigóttartalmaz, melynek a gazdasejtben való működőképessége legalább egyspecifikűs, az említett gazdasejtre nézve idegen fehérje jelenlététigényli. A találmány tárgya a megfelelő, az említett DNS-mőlekűlákelőállítására szőlgáló eljárás is, valamint azők alkalmazása agénterápiában. ŕ
HU9900018A 1995-09-15 1996-09-13 Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás elõállítására és génterápiában való alkalmazása HU224400B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9510825A FR2738842B1 (fr) 1995-09-15 1995-09-15 Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
PCT/FR1996/001414 WO1997010343A1 (fr) 1995-09-15 1996-09-13 Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique

Publications (3)

Publication Number Publication Date
HUP9900018A1 true HUP9900018A1 (hu) 1999-04-28
HUP9900018A3 HUP9900018A3 (en) 2001-10-29
HU224400B1 HU224400B1 (hu) 2005-08-29

Family

ID=9482580

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900018A HU224400B1 (hu) 1995-09-15 1996-09-13 Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás elõállítására és génterápiában való alkalmazása

Country Status (20)

Country Link
US (3) US6977174B2 (hu)
EP (3) EP0850310B1 (hu)
JP (3) JP3818665B2 (hu)
KR (1) KR100522369B1 (hu)
AT (3) ATE284966T1 (hu)
BR (1) BRPI9610511B8 (hu)
CA (1) CA2229307C (hu)
CZ (1) CZ294525B6 (hu)
DE (3) DE69636878T2 (hu)
DK (3) DK0850310T3 (hu)
ES (3) ES2281721T3 (hu)
FR (1) FR2738842B1 (hu)
HU (1) HU224400B1 (hu)
IL (4) IL123641A0 (hu)
NO (1) NO323975B1 (hu)
PT (3) PT850310E (hu)
SK (1) SK285317B6 (hu)
TW (1) TWI231826B (hu)
WO (1) WO1997010343A1 (hu)
ZA (1) ZA967640B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7038026B2 (en) * 2000-05-26 2006-05-02 Centelion Purification of a triple heli formation with an immobilized oligonucleotide
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US6821759B1 (en) 1997-06-23 2004-11-23 The Rockefeller University Methods of performing homologous recombination based modification of nucleic acids in recombination deficient cells and use of the modified nucleic acid products thereof
US6156574A (en) 1997-06-23 2000-12-05 The Rockefeller University Methods of performing gene trapping in bacterial and bacteriophage-derived artificial chromosomes and use thereof
CZ299473B6 (cs) 1997-06-30 2008-08-06 Rhone-Poulenc Rorer S. A. Nukleová kyselina a elektrické pole jako sdruženýprodukt pro prenos nukleové kyseliny do bunek prícne pruhovaného svalstva
US6022716A (en) 1998-04-10 2000-02-08 Genset Sa High throughput DNA sequencing vector
WO2000075299A1 (en) * 1999-06-07 2000-12-14 Cell Genesys, Inc. Hybrid yeast-bacteria cloning system and uses thereof
AU6229800A (en) * 1999-07-20 2001-02-05 Rockefeller University, The Conditional homologous recombination of large genomic vector inserts
FR2821855B1 (fr) † 2001-03-09 2004-04-02 Cayla Genes synthetiques et plasmides bacteriens depourvus de cpg
FR2822476B1 (fr) * 2001-03-23 2004-04-02 Aventis Pharma Sa Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
AU2002325346A1 (en) 2001-07-05 2003-01-21 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US7049121B2 (en) 2001-12-20 2006-05-23 Applied Molecular Evolution Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
FI116068B (fi) 2003-09-15 2005-09-15 Fit Biotech Oyj Plc Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi
JP4581851B2 (ja) * 2004-07-27 2010-11-17 セイコーエプソン株式会社 電気光学装置の駆動回路及び駆動方法、電気光学装置並びに電子機器
CA2608636C (en) * 2005-05-17 2015-02-10 Frank Koentgen Sequential cloning system
US8716021B2 (en) * 2005-09-07 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
EP2386564B1 (en) * 2005-10-01 2014-07-16 Charles Stout Regulatable fusion promoters
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
CN102124102B (zh) * 2008-07-18 2013-12-18 麦克赛特股份有限公司 优化电穿孔的方法
EP2221066A1 (en) 2009-02-18 2010-08-25 Sanofi-Aventis Use of VgII3 activity modulator for the modulation of adipogenesis
EP2547768B1 (en) 2010-03-17 2015-12-30 Association Institut de Myologie Modified u7 snrnas for treatment of neuromuscular diseases
US9403880B2 (en) 2010-11-26 2016-08-02 Institut Pasteur Identification of a human gyrovirus and applications
WO2013083753A2 (en) 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
WO2014035457A1 (en) 2012-08-29 2014-03-06 Nature Technology Corporation Dna plasmids with improved expression
WO2014077863A1 (en) 2012-11-19 2014-05-22 Nature Technology Corporation Replicative minicircle vectors with improved expression
WO2014153205A1 (en) * 2013-03-14 2014-09-25 Epeius Biotechnologies Corporation Thymidine kinase diagnostic assay for gene therapy applications
WO2019057774A1 (en) 2017-09-19 2019-03-28 Deutsches Krebsforschungszentrum NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS
EP3456821B2 (en) 2017-09-19 2024-01-24 Deutsches Krebsforschungszentrum Non-integrating dna vectors for the genetic modification of cells
SG11202009009UA (en) 2018-03-21 2020-10-29 Nature Tech Corporation Viral and non-viral nanoplasmid vectors with improved production
WO2023241567A1 (zh) * 2022-06-13 2023-12-21 南京金斯瑞生物科技有限公司 一种可提高无筛选标签质粒制备效率的野生型-突变体π蛋白切换表达系统

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190495A (en) * 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4727028A (en) * 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4654307A (en) * 1983-02-17 1987-03-31 The Research Foundation Of State University Of New York Novel bacteria containing a plasmid having a tRNA code
US4761367A (en) * 1984-11-07 1988-08-02 The University Of North Carolina At Chapel Hill Vectors suitable for detection of eukaryotic DNA regulatory sequences
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
US5198343A (en) * 1986-08-05 1993-03-30 Transgene, S.A. Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5510099A (en) * 1987-05-01 1996-04-23 Stratagene Mutagenesis testing using transgenic non-human animals carrying test DNA sequences
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
JPH03187383A (ja) * 1989-09-04 1991-08-15 Takeda Chem Ind Ltd 発現プラスミドおよびその用途
EP0485701A1 (en) * 1990-09-28 1992-05-20 American Cyanamid Company Insertion of DNA by modified transposons
TW201794B (hu) * 1991-05-03 1993-03-11 American Cyanamid Co
US5714323A (en) * 1991-08-30 1998-02-03 The University Of Medecine And Dentistry Of New Jersey Over expression of single-stranded molecules
US5444149A (en) * 1992-05-11 1995-08-22 Duke University Methods and compositions useful in the recognition, binding and expression of ribonucleic acids involved in cell growth, neoplasia and immunoregulation
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
WO1995005452A2 (en) * 1993-08-12 1995-02-23 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
IL109558A (en) * 1994-05-04 2004-08-31 Yissum Res Dev Co DNA structures Derived from the SV40 virus that include DNA sequences External
AU2946695A (en) * 1994-07-08 1996-02-09 Schering Corporation Method for identifying nucleic acids encoding c-fos promoter activating proteins
DE4428402A1 (de) * 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
US5792647A (en) * 1995-02-13 1998-08-11 The Johns Hopkins University Bacterial catabolism of chitin
US6254874B1 (en) * 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
US5763270A (en) * 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US7364894B2 (en) * 1995-09-15 2008-04-29 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US5851808A (en) * 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
US5874259A (en) * 1997-11-21 1999-02-23 Wisconsin Alumni Research Foundation Conditionally amplifiable BAC vector

Also Published As

Publication number Publication date
NO981044L (no) 1998-03-10
SK285317B6 (sk) 2006-10-05
ATE492642T1 (de) 2011-01-15
IL173399A (en) 2010-11-30
DK0850310T3 (da) 2005-04-25
PT850310E (pt) 2005-05-31
WO1997010343A1 (fr) 1997-03-20
ES2357098T3 (es) 2011-04-18
BR9610511B1 (pt) 2010-10-19
US20090149406A1 (en) 2009-06-11
DK1724354T3 (da) 2011-04-04
TWI231826B (en) 2005-05-01
SK34798A3 (en) 1998-11-04
MX9802005A (es) 1998-08-30
EP0850310A1 (fr) 1998-07-01
DK1508620T3 (da) 2007-05-29
FR2738842B1 (fr) 1997-10-31
BR9610511A (pt) 1999-01-26
JP2000501281A (ja) 2000-02-08
JP2006136328A (ja) 2006-06-01
US20010014476A1 (en) 2001-08-16
EP0850310B1 (fr) 2004-12-15
PT1508620E (pt) 2007-05-31
FR2738842A1 (fr) 1997-03-21
HU224400B1 (hu) 2005-08-29
ATE284966T1 (de) 2005-01-15
JP4585435B2 (ja) 2010-11-24
AU6992496A (en) 1997-04-01
DE69638314D1 (de) 2011-02-03
DE69636878T2 (de) 2007-11-08
NO323975B1 (no) 2007-07-30
EP1724354A2 (fr) 2006-11-22
HUP9900018A3 (en) 2001-10-29
IL123641A0 (en) 1998-10-30
IL207348A0 (en) 2010-12-30
CA2229307A1 (fr) 1997-03-20
CZ78898A3 (cs) 1998-06-17
US20090130674A1 (en) 2009-05-21
ZA967640B (en) 1997-03-25
ES2281721T3 (es) 2007-10-01
BRPI9610511B8 (pt) 2016-11-08
JP3818665B2 (ja) 2006-09-06
EP1724354B1 (fr) 2010-12-22
KR100522369B1 (ko) 2006-10-24
US6977174B2 (en) 2005-12-20
EP1508620A1 (fr) 2005-02-23
IL173399A0 (en) 2006-06-11
AU728231B2 (en) 2001-01-04
EP1508620B1 (fr) 2007-01-24
KR19990044683A (ko) 1999-06-25
JP4756014B2 (ja) 2011-08-24
IL123641A (en) 2006-06-11
NO981044D0 (no) 1998-03-10
DE69634043T2 (de) 2005-08-18
ES2233975T3 (es) 2005-06-16
CA2229307C (fr) 2013-06-11
JP2007325603A (ja) 2007-12-20
DE69634043D1 (de) 2005-01-20
CZ294525B6 (cs) 2005-01-12
DE69636878D1 (de) 2007-03-15
PT1724354E (pt) 2011-03-09
EP1724354A3 (fr) 2008-10-29
ATE352630T1 (de) 2007-02-15

Similar Documents

Publication Publication Date Title
HUP9900018A1 (hu) Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására
CY1112110T1 (el) Κυκλικο μοριο dna το οποιο διαθετει μια συμβατικη αφετηρια αντιγραφης, η διαδικασια παρασκευης του και η χρηση του στην γονιδιακη θεραπεια
HUP9900868A2 (hu) Heterológ gének kromoszomális expressziója bakteriális sejtekben
ATE366806T1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
NO973685L (no) Multi-tumor avvikende vekstgener
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
DE69534733D1 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
HUP0203537A2 (hu) Célmolekula transzgénikus állatban történő előállítására és tisztítására szolgáló eljárások
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
HUP9802681A1 (hu) Onkogénnel vagy vírussal szabályozott expressziós rendszerek
DE69739346D1 (de) Gereinigtes sr-p70 protein
DE59712554D1 (de) Rekombinante expression von s-layer-proteinen
HUP9801681A2 (hu) Mutáns proteinek
HUP9901346A2 (hu) Deltap62 polipeptid és variánsai, ezeket kódoló nukleinsav-szekvenciák és felhasználásuk
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
ES2152976T3 (es) Proteina crp mutante, procedimientos y medios para su fabricacion y su utilizacion.
HUP0400915A2 (hu) Növényi reprodukciós proteinek

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050714

GB9A Succession in title

Owner name: AVENTIS PHARMA S.A., FR

Free format text: FORMER OWNER(S): AVENTIS PHARMA S.A., FR; CENTELION, FR; GENCELL SA,, FR; RHONE-POULENC RORER S.A., FR

MM4A Lapse of definitive patent protection due to non-payment of fees